These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 33528794)

  • 41. In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone.
    Otani T; Tanaka M; Ito E; Kurosaka Y; Murakami Y; Onodera K; Akasaka T; Sato K
    Antimicrob Agents Chemother; 2003 Dec; 47(12):3750-9. PubMed ID: 14638477
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
    Peric M; Browne FA; Jacobs MR; Appelbaum PC
    Clin Ther; 2003 Jan; 25(1):169-77. PubMed ID: 12637118
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia.
    Biedenbach DJ; Farrell DJ; Flamm RK; Liverman LC; McIntyre G; Jones RN
    Int J Antimicrob Agents; 2012 Apr; 39(4):321-5. PubMed ID: 22306239
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vivo pharmacodynamics of lefamulin, the first systemic pleuromutilin for human use, in a neutropenic murine thigh infection model.
    Wicha WW; Craig WA; Andes D
    J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii5-iii10. PubMed ID: 30949706
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Focus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
    Jones TM; Johnson SW; DiMondi VP; Wilson DT
    Infect Drug Resist; 2016; 9():119-28. PubMed ID: 27354817
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ceftaroline activity tested against bacterial isolates from pediatric patients: results from the assessing worldwide antimicrobial resistance and evaluation program for the United States (2011-2012).
    Sader HS; Mendes RE; Farrell DJ; Flamm RK; Jones RN
    Pediatr Infect Dis J; 2014 Aug; 33(8):837-42. PubMed ID: 25222304
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY Antimicrobial Surveillance Program.
    Gordon KA; Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2003 Aug; 46(4):285-9. PubMed ID: 12944021
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and Pharmacokinetics Following Oral or Intravenous Lefamulin in Adults With Cystic Fibrosis.
    Sawicki GS; Wicha WW; Hiley TS; Close NC; Gelone SP; Guico-Pabia CJ
    Clin Ther; 2024 Feb; 46(2):96-103. PubMed ID: 38195348
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An overview of lefamulin for the treatment of community acquired bacterial pneumonia.
    Falcó V; Burgos J; Almirante B
    Expert Opin Pharmacother; 2020 Apr; 21(6):629-636. PubMed ID: 31958020
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
    Jorgenson MR; DePestel DD; Carver PL
    Ann Pharmacother; 2011 Nov; 45(11):1384-98. PubMed ID: 22009993
    [TBL] [Abstract][Full Text] [Related]  

  • 53.
    Flamm RK; Rhomberg PR; Sader HS
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971877
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Review of Omadacycline for Potential Utility in the Military Health System for the Treatment of Wound Infections.
    Zurawski DV; Serio AW; Black C; Pybus B; Akers KS; Deck DH; Johnson S; Chattagul S; Noble SM; Raynor M; Lanteri CA
    Mil Med; 2024 May; 189(5-6):e1353-e1361. PubMed ID: 37963013
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetic and pharmacodynamic evaluation of ceftaroline fosamil.
    Merker A; Danziger LH; Rodvold KA; Glowacki RC
    Expert Opin Drug Metab Toxicol; 2014 Dec; 10(12):1741-50. PubMed ID: 25347329
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from adults in China during 2009 and 2010].
    Wang H; Liu YL; Chen MJ; Xu YC; Sun HL; Yang QW; Hu YJ; Cao B; Chu YZ; Liu Y; Zhang R; Yu YS; Sun ZY; Zhuo C; Ni YX; Hu BJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):113-9. PubMed ID: 22455967
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A critical review of oxazolidinones: an alternative or replacement for glycopeptides and streptogramins?
    Zhanel GG; Shroeder C; Vercaigne L; Gin AS; Embil J; Hoban DJ
    Can J Infect Dis; 2001 Nov; 12(6):379-90. PubMed ID: 18159365
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Omadacycline in the treatment of community-acquired bacterial pneumonia in patients with comorbidities: a
    Rodriguez GD; Warren N; Yashayev R; Chitra S; Amodio-Groton M; Wright K
    Front Med (Lausanne); 2023; 10():1225710. PubMed ID: 37575994
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lefamulin (Xenleta) for community-acquired bacterial pneumonia.
    Med Lett Drugs Ther; 2019 Sep; 61(1581):145-148. PubMed ID: 31599865
    [No Abstract]   [Full Text] [Related]  

  • 60. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
    Jones RN; Sader HS; Stilwell MG; Fritsche TR
    Diagn Microbiol Infect Dis; 2007 May; 58(1):1-7. PubMed ID: 17408904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.